Tata Consultancy Services (TCS), a global IT services, consulting and business solutions company, has launched TCS ADD™ AgentHub, an enterprise-ready, role-based AI platform designed to help pharmaceutical companies deploy agentic AI across drug development at scale. The platform aims to transform clinical development and pharmacovigilance operations while addressing critical requirements around regulatory compliance, governance, oversight and auditability.
Addressing AI Challenges in Pharmaceutical R&D
Pharmaceutical companies operate in highly regulated environments, making the adoption of AI across research and development particularly complex. At the same time, growing data volumes, fragmented technology systems and evolving regulatory requirements are increasing pressure across the drug development and drug safety value chain. TCS ADD™ AgentHub addresses these challenges by providing a structured framework in which AI agents operate with defined roles, clear oversight and built-in auditability. Furthermore, pharmaceutical companies can configure their own AI agent hub and deploy AI agents across multiple clinical workflows. The platform also supports streamlined integration, enabling organisations to accelerate AI adoption while maintaining regulatory requirements.
Delivering Measurable Efficiency Gains
Built on the TCS ADD™ framework, AgentHub is designed to deliver measurable operational improvements across drug development and pharmacovigilance. According to TCS, solutions powered by the platform have demonstrated:
Up to 40% efficiency gains in clinical data management activities.
Up to 30% reduction in clinical study build efforts through metadata-driven automation.
Up to 30% cost savings in end-to-end safety case processing.
Up to 50% reduction in quality control effort through AI-powered safety agents.
These capabilities can help pharmaceutical organisations improve productivity while allowing scientific and clinical teams to focus more extensively on higher-value activities.
Combining Human Expertise with AI Agents
TCS ADD™ AgentHub is built around a Human + AI Operating Model. Under this approach, AI agents become part of enterprise workflows while human professionals retain responsibility for governance, oversight and critical decision-making. This model allows organisations to benefit from automation without removing human accountability from highly regulated drug development and safety processes. Debashis Ghosh, President, Lifesciences and Healthcare, TCS, said, “TCS ADD™ AgentHub is a role-based, enterprise-ready, and trusted AI platform that will enable our customers to accelerate drug development using agentic AI at scale.” He added that the platform can help organisations move from reactive operations towards proactive, scalable and audit-ready processes while responding to an evolving regulatory environment.
AI Agents Support Clinical Development and Drug Safety
TCS ADD™ AgentHub supports a broad range of workflows across clinical development and pharmacovigilance. Its AI workforce can assist with activities such as Individual Case Safety Report (ICSR) intake, data entry and coding, safety case review, literature analysis, study design, protocol digitisation, clinical data review, SDTM transformation and medical monitoring assistance. TCS is developing an expanding catalogue of AI agents that organisations can select according to their specific requirements and technology landscape. Companies can progressively deploy these agents with minimal integration and implementation effort. Consequently, organisations can adopt agentic AI across critical processes without having to transform their entire technology environment at once.
Standardising Agentic AI Across Drug Development
By creating a standardised approach to deploying AI agents, TCS ADD™ AgentHub aims to help pharmaceutical companies scale AI beyond individual use cases. The platform can enable AI workers to perform repetitive and process-intensive activities while human experts concentrate on scientific analysis, clinical decision-making and other high-value responsibilities. This approach could ultimately help pharmaceutical organisations improve operational efficiency while strengthening the scalability and governance of AI across regulated R&D environments.
TCS Advances Its AI-First Strategy
The launch of TCS ADD™ AgentHub further strengthens TCS’s broader AI-first strategy and its ambition to become a leading AI-driven technology services company. By leveraging the cognitive intelligence capabilities of the TCS ADD™ suite, TCS aims to help customers build secure, predictive and scalable digital ecosystems. As per the press release, with agentic AI increasingly moving from experimentation towards enterprise deployment, TCS ADD™ AgentHub positions AI agents as an integral part of pharmaceutical workflows—potentially reshaping how companies manage clinical trials, drug development and pharmacovigilance at scale.
